Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 2 STS-J01 study in Japan met its primary endpoint for PEDMARK®.
FENNEC PHARMACEUTICALS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 2 STS-J01 study in Japan met its primary endpoint for PEDMARK®
- Significant hearing protection demonstrated in cisplatin-treated patients
- No evidence of interference with cisplatin antitumor activity, supporting PEDMARK’s clinical positioning
- Japan data may strengthen regulatory and commercial prospects for PEDMARK® beyond existing markets
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 STS-J01 met its primary endpoint, with ASHA-defined hearing loss at 24.0% versus 56.4% historical benchmark
- 95.8% objective tumor response rate supports six-hour PEDMARK administration without apparent cisplatin antitumor interference
- No Grade 3 or Grade 4 hearing loss and no serious adverse event attributed to PEDMARK strengthen the Japan registration case
- Fennec is pursuing Japanese registration while seeking regional partnering or licensing opportunities
- Japan expansion remains a catalyst, but approval and commercial uptake remain subject to regulatory review and additional execution risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FENNEC PHARMACEUTICALS INC. 8-K filings
Get the next FENC 8-K as it lands
Follow FENC for push alerts, or ask the research agent what this filing means.